Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Inclusion Criteria: * ≥ 18 and ≤ 70 years of age * Histological confirmed advanced or metastatic adenocarcinoma of the stomach * Have failed for at least 2 lines of chemotherapy * Life expectancy of at least 12 weeks. * Eastern Cooperative Oncology Group Performance Status of 0 or 1 within 1 week before randomization. * At least one measurable lesion beyond stomach (larger than 10 mm in diameter by spiral CT scan) * Duration from the last therapy is more than 6 weeks for nitroso or mitomycin * More than 4 weeks for operation or radiotherapy * More than 4 weeks for cytotoxic agents or growth inhibitors * Adequate hepatic, renal, heart, and hematologic functions (HB ≥ 90g/L,platelets \> 80 ×10 E+9/L, neutrophil \> 1.5 × 10 E+9/L, serum creatinine ≤ 1× upper limit of normal(ULN), bilirubin \< 1.25× ULN, and serum transaminase ≤ 2.5× ULN). Exclusion Criteria: * Pregnant or lactating women * History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg). * Any factors that influence the usage of oral administration; Evidence of Central Nerves System(CNS) metastasis * Intercurrence with one of the following: coronary artery disease, arrhythmia ,heart failure and proteinuria ≥ (+) * International Normalize Ratio (INR) \> 1.5 and activated partial thromboplastin time（APPT） \> 1.5 × ULN * Abuse of alcohol or drugs * Certain possibility of gastric or intestine hemorrhage * Less than 4 weeks from the last clinical trial * Prior VEGFR inhibitor treatment * Disability of serious uncontrolled intercurrence infection Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, Pneumoconiosis, radiation pneumonitis, drug-related pneumonia, Pulmonary function damaged seriously etc.